Premarket Stock Movers — September 16, 2026: Why MEDS, ZTG, DLXY, TPST & BENF Are Surging

MEDS — DataMeds AI, Inc. (+384.2%)

DataMeds AI is up a staggering +384.2% in premarket trading, touching $4.19 on 49.8 million shares — against a 20-day average of just 667,259. That is nearly 75× its normal daily volume before the opening bell has even rung, making this the most explosive move of the morning by a wide margin.

Why it's moving: According to Yahoo Finance and headlines from September 15, DataMeds AI has acquired the Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO businesses from Axe Compute. The seller, Axe Compute, confirmed it has completed its transition to a Neocloud GPU-as-a-Service platform, divesting these healthcare AI assets to MEDS. A TipRanks piece from September 15 had already flagged the stock up nearly 200% on that day's news — this morning's premarket is extending that move further.

Technical picture: The prior-day chart carries a conviction score of 0/100 and a grade of D, which reflects where MEDS was sitting before this catalyst landed. RSI had been deeply oversold at 24, and the stock was sitting 96.1% below its 52-week high — typical of a deeply distressed micro-cap before a binary news event. The short-squeeze score is modest at 23/100, with short interest of only ~174,000 shares and just 0.2 days to cover (meaning it takes short sellers less than half a trading day to buy back their borrowed shares), so this move is almost entirely catalyst-driven rather than a squeeze.

Risk check: MEDS carries a market cap of roughly $2.6 million — smaller than many people's homes. Stocks this tiny can move hundreds of percent on a single press release and then surrender the gains just as fast. The stock remains 96% off its 52-week high even after this premarket spike, which illustrates how violent the prior decline was. This is not a setup StockSetups scores highly on technicals — it is pure news momentum in one of the most speculative corners of the market.

ZTG — Zenta Group Co Ltd (+253.4%)

Zenta Group, a Consumer Discretionary micro-cap, is surging +253.4% to $2.44 on 56.2 million shares premarket — roughly 15.5× its 20-day average of 3.6 million. That level of relative volume (the ratio of current volume to the norm) before the open is a strong signal that something significant is attracting attention.

Why it's moving: There are no news headlines on file for ZTG this morning, and no recent SEC filing beyond routine foreign-issuer 6-K filings on September 9 and September 14. With no confirmed catalyst available, this move appears to be momentum- and technically-driven. It is possible an untracked press release, social media post, or overseas news item is fueling the action — but based solely on the data at hand, the catalyst is unclear.

Float and squeeze read: ZTG's squeeze score is 11/100, short interest sits at ~210,000 shares, and days to cover is 0.2 — so a traditional short squeeze is not the obvious explanation here either. What is notable is the sheer volume relative to what is likely a very small tradeable float on a stock with a $8.0M market cap sitting 93.4% below its 52-week high. Small pools of shares combined with concentrated buying orders can produce outsized percentage moves very quickly.

Risk check: Without a clear fundamental catalyst, moves like ZTG's are among the hardest to trade safely. The stock carries a conviction score of 0/100, a technical grade of D, and an RSI of 34 — none of which suggests institutional accumulation. Chasing a +253% premarket move with no confirmed news is a high-risk proposition; the move could evaporate entirely once regular-session liquidity arrives.

DLXY — Delixy Holdings Ltd (+134.1%)

Delixy Holdings, a small-cap Energy name, is trading +134.1% higher to $0.97 on 88.9 million shares — an eye-watering 311× its 20-day average of 286,193 shares. That relative volume figure is extraordinary even by the standards of this morning's active list.

Why it's moving: Yahoo Finance reports this morning that Delixy Holdings has signed a non-binding letter of intent (LOI) for a strategic transaction involving up to a 48% interest in the East Kazakhstan Sarybulak Oil Field. An LOI is a preliminary agreement — not a binding contract — that signals the intent to negotiate a deal. Still, for a company with a market cap of just $6.8M, a potential stake in an operating oil field is the kind of headline that can reorder the entire narrative around a stock overnight.

Technical picture: The prior-day chart shows a bearish moving-average (MA) stack, a technical rank of 22, and a conviction score of 0/100 — again, this was a deeply-depressed chart before the news hit. RSI was sitting at a neutral 51, and the stock was 93.8% below its 52-week high. The squeeze score is 32/100, with a free float of 69.7% and 3.0 days to cover — slightly more short exposure than MEDS or ZTG, which means some short covering could be amplifying the move alongside the fundamental catalyst.

Risk check: "Non-binding" is the key phrase in any LOI announcement. These deals frequently fail to close, restructure materially, or take far longer than investors expect. Delixy operates in a micro-cap, illiquid space with a grade-D technical profile. The volume surge is enormous, but it is happening on very thin historical float trading, meaning a single large sell order can move the price dramatically in either direction. For more context on how volume spikes like this behave after the open, see our piece on gap-and-go setups.

TPST — Tempest Therapeutics, Inc. (+39.4%)

Tempest Therapeutics is jumping +39.4% to $1.04 on 20.6 million shares — roughly 103× its 20-day average of 200,007. The Healthcare micro-cap is building on a dramatic move that was already underway in yesterday's after-hours session.

Why it's moving: Multiple sources confirm that Tempest has secured an exclusive option agreement with Senlang Biotechnology to license a clinical-stage CD7-targeted lentiviral in-vivo CAR-T platform, along with a BCMA/GPRC5D candidate. CAR-T (chimeric antigen receptor T-cell) therapy is a cutting-edge approach to cancer treatment where a patient's own immune cells are genetically re-engineered to attack cancer. An "in-body" or in-vivo CAR-T platform means the genetic reprogramming potentially happens inside the patient's body rather than in a lab — a technically significant distinction. Benzinga noted shares surged 66.53% after hours on the deal, and this morning's premarket is continuing that momentum.

Squeeze dynamics: TPST carries a squeeze score of 58/100 — the highest of the five movers this morning — with a free float of only 40.6% (meaning less than half the outstanding shares are freely tradeable) and 2.0 days to cover. A low float amplifies both upward and downward price moves, because there are fewer shares available to absorb buying or selling pressure. Combined with the high-profile biotech catalyst, this is a meaningful squeeze setup layered on top of real news.

Watch the dilution signal: The September 15 SEC filings include an 8-K flagged as dilution and an S-1 registration statement — both of which can signal that the company may be planning to issue new shares. New share issuance (dilution) directly reduces the value of existing shares and is a bearish counterweight to any bullish catalyst. The prior-day chart shows a bearish MA stack, RSI of 29, and a conviction score of just 12/100. This morning's CAR-T news is real and significant for the story, but the structural risks are real too.

BENF — Beneficient (+36.1%)

Beneficient, a Financials-sector micro-cap, is gaining +36.1% to $0.82 on 63.6 million shares — about 73× its 20-day average of 868,969. A short-sale restriction (SSR) is active on the stock, meaning regulators have placed limits on additional short-selling after a significant prior-day decline — itself a sign of how volatile this name has been recently.

Why it's moving: Multiple sources this morning — including TipRanks, Investing.com, and Stock Titan — confirm that Beneficient's CEO and directors have been purchasing shares of the company through private transactions. Insider buying (when a company's own executives put their personal money into the stock at open-market or private prices) is often read by the market as a vote of confidence in the company's future. An 8-K filed with the SEC on September 16 appears to disclose these purchases formally.

Smart-money and squeeze read: Beneficient has the most interesting institutional and squeeze profile of this morning's five names. Its squeeze score is 58/100 (tied with TPST for highest), its free float is just 9.3% — meaning only about 1 in 10 shares are freely tradeable — and its days to cover stands at 14.0, the highest on today's list by far. Days to cover measures how many trading days it would take short sellers to buy back all their borrowed shares at current average volume. At 14 days, any sustained buying pressure could force short sellers into a scramble. The smart-money score is 39/100, with one 13D/G stake (a regulatory filing required when an investor accumulates more than 5% of a company's shares) disclosing a 7.5% position.

Technical nuance: BENF's RSI is deeply oversold at 19, the MA stack is bearish, and the stock sits 93.2% below its 52-week high — but its RS rating of 95 is a standout. Relative strength (RS) measures how a stock has performed vs. the broader market over a set period; a score of 95 means it has outperformed 95% of all stocks on that metric. That combination of extreme oversold technicals, a tiny float, high short interest, and now insider buying is exactly the kind of setup that produces outsized squeeze candidates — though SSR restrictions and the stock's distressed profile mean risk remains very high.

The bottom line

This morning's five premarket movers — MEDS, ZTG, DLXY, TPST, and BENF — illustrate just how quickly micro-cap and small-cap stocks can reprice on news, rumors, or unexplained momentum before the regular session opens. A company acquisition (MEDS), an oil-field LOI (DLXY), a biotech licensing deal (TPST), and insider buying (BENF) are all real catalysts worth understanding; ZTG's catalyst remains unclear as of this writing.

But premarket trading is thinner and more volatile than the regular session. Prices quoted before 9:30 AM ET can shift dramatically — in either direction — once the full market opens and institutional participants add liquidity. Stocks that are up 100%, 200%, or 384% before the bell have often already reflected (or over-reflected) the news. Chasing extended premarket movers is one of the highest-risk moves a trader can make. Chart patterns fail, squeezes reverse, and deals fall apart.

None of this is financial advice or a recommendation to buy or sell any security. Always do your own research, size positions appropriately for your risk tolerance, and use stop-losses.

StockSetups scans the full ~12,300-stock US universe every premarket morning — detecting chart patterns, computing conviction and squeeze scores, and surfacing the setups with the most technical merit before the open. Check back after today's close for a full recap of how these names and others traded in the regular session, or revisit yesterday's premarket recap and yesterday's after-close recap for context on names like VEEA that have been active all week.